Why Molecular Templates (MTEM) Stock Is Down 77% Today
Why Molecular Templates (MTEM) Stock Is Down 77% Today
Molecular Templates will reduce its workforce, retaining only key management for winding up the business and exploring remaining strategic alternatives. The company also plans to wind down its Phase 1 clinical trials but will continue discussions with the FDA for one of its drugs, MT-0169. Molecular Templates Inc (NASDAQ:MTEM) shares are trading lower by 77% to $0.35 during Monday's session after the company announced it approved the liquidation and wind-up of the company.
Molecular Templates Inc (NASDAQ:MTEM)股票在週一交易中下跌77%，至0.35美元，因該公司宣佈批准了公司的清算和解散。
What Happened: On October 11, Molecular Templates approved a plan to liquidate and wind up the company, pending stockholder approval, due to a lack of viable strategic alternatives. The company says it had been exploring options for over a year but found no suitable outcomes.
發生了什麼：10月11日，Molecular Templates批准了一項計劃，以待股東批准的方式清算和解散公司，因爲缺乏可行的戰略替代方案。該公司表示，已經探討了一年多的選項，但沒有找到合適的解決方案。
The board is also seeking stockholder approval for a plan of distribution, although it does not expect that shareholders will receive value for their shares upon dissolution.
董事會還尋求股東批准一項分配計劃，儘管它不期望股東在解散後會獲得股票價值。
Molecular Templates will reduce its workforce, retaining only key management for winding up the business and exploring remaining strategic alternatives. The company also plans to wind down its Phase 1 clinical trials but will continue discussions with the FDA for one of its drugs, MT-0169.
Molecular Templates將裁減工作人員，僅保留關鍵管理人員來解散業務並探索剩餘的戰略選擇。該公司還計劃關閉其第1階段臨床試驗，但將繼續與FDA討論其一種藥物Mt-0169。
Despite ongoing efforts to maximize asset value, there is no assurance of a positive outcome or any shareholder distribution. The workforce reduction is expected to be completed in October 2024, with minimal associated costs.
儘管不斷努力最大化資產價值，但無法確保有積極結果或任何股東分配。預計工作人員減少將於2024年10月完成，附帶成本很低。
Read Also: Bank Of America Stock Shows Strength As Buffett Sells: Bulls In Control Ahead Of Q3 Earnings
閱讀更多：美國銀行股展現強勢，巴菲特賣出：看漲控制第三季度業績前的情況
According to data from Benzinga Pro, MTEM has a 52-week high of $6.69 and a 52-week low of $0.30.
根據Benzinga Pro的數據，在過去52周，MTEm的最高股價爲6.69美元，最低股價爲0.30美元。
譯文內容由第三人軟體翻譯。
